Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study ...
Arvinas is pushing ahead with plans to expand development of its prostate cancer prospect ARV-766 into earlier-line settings. The biotech linked the protein degrader to declines in the PSA biomarker ...
– 42% of patients with AR ligand binding domain (LBD) mutations achieved PSA 50; in patients with AR L702H mutations, 3 of 5 achieved PSA 50 – – ARV-766 was well-tolerated, and activity in a heavily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results